Monkeypox Vaccine Market Growth, Demand and Challenges of the Key Industry Players 2024-32

1
Global Monkeypox Vaccine Market Research and
Forecast Report 2024-2032

• Format PDFEXCEL

2023 IMARC All Rights Reserved
2
About IMARC Group

• IMARC Group is a global management consulting
  firm that helps the worlds most ambitious
  changemakers to create a lasting impact. Across
  the six major continents and 100 countries, we
  work alongside our business partners as one team
  with a common ambition to achieve unparalleled
  results, gain a competitive edge, and transform
  industries. IMARC Group excels in understanding
  its clients business priorities and delivering
  tailored solutions that drive meaningful
  outcomes. Our client base spans over 3,000
  organizations in the private, public, and social
  sectors, ranging from high-growth startups to
  Fortune 500 companies.
• We provide a comprehensive suite of market entry
  and expansion services. Our offerings include
  thorough market assessment, feasibility studies,
  company incorporation assistance, factory setup
  support, regulatory approvals and licensing
  navigation, branding, marketing and sales
  strategies, competitive landscape and
  benchmarking analyses, pricing and cost research,
  and procurement research. These services are
  designed to assist companies in evaluating market
  opportunities, setting up new entities,
  navigating regulatory landscapes, boosting brand
  visibility, analyzing competitors, and optimizing
  procurement strategies.

3
Report Highlight and Description

• According to the latest report by IMARC Group,
  titled "Monkeypox Vaccine Market Global Industry
  Trends, Share, Size, Growth, Opportunity and
  Forecast 2024-2032," the global monkeypox vaccine
  market size reached US 86.6 Million in 2023.
• Factors Affecting the Growth of the Monkeypox
  Vaccine Industry
• Global Health Initiatives and Funding Increases
• The rise in international focus on infectious
  diseases is driving the demand for vaccines
  against emerging threats like monkeypox.
  Governments, global health bodies, and private
  entities are increasingly investing in vaccine
  development and distribution frameworks to
  prevent widespread outbreaks.
• This rise in funding not only facilitates the
  accelerated development and approval of new
  vaccines but also enhances the manufacturing
  capabilities of pharmaceutical companies. As a
  result, the capacity to produce vaccines at scale
  and the ability to rapidly respond to emerging
  health crises are markedly improving.

4
Report Highlight and Description

• Rising Incidence of Monkeypox Cases
• The noticeable increase in monkeypox cases across
  multiple regions globally is supporting the
  growth of the market. This uptick is linked to
  several factors, including greater human
  interaction with animal vectors and international
  travel, which facilitates the cross-border
  transmission of the virus.
• The growing awareness among public health
  authorities and surveillance of monkeypox are
  leading to improved diagnosis rates, subsequently
  increasing the perceived need for vaccination.
  The urgent demand for effective preventive
  measures against a potential outbreak encourages
  healthcare systems and governments to procure and
  stockpile adequate vaccine supplies.
• Advancements in Vaccine Technology
• Recent technological advancements in vaccine
  research and development (RD) are bolstering the
  market growth. Innovations, such as messenger
  ribonucleic acid (mRNA) vaccine technology, are
  being adapted for other infectious diseases,
  including monkeypox.

5
Report Highlight and Description

• These technologies allow for quicker development
  and potentially more effective vaccines,
  increasing their adoption rate. Moreover, the
  ability to adjust existing platforms to target
  new pathogens reduces the time and cost
  associated with vaccine development, making the
  process more efficient and scalable. This factor
  not only enhances the production capacity of
  vaccine manufacturers but also improves the
  global readiness to combat emerging infectious
  diseases.
• Request for a PDF sample of this report
  https//www.imarcgroup.com/monkeypox-vaccine-marke
  t/requestsample

6
Report Description

• Global Monkeypox Vaccine Market Trends
• Increased public awareness about monkeypox and
  its transmission dynamics plays a significant
  role in driving vaccine demand. As awareness
  grows, so does the willingness of the public to
  receive vaccinations, influenced by targeted
  health communication strategies and public health
  campaigns. Furthermore, governments implementing
  robust health policies that include vaccination
  programs as part of their disease prevention and
  control plans also spur market growth.
• These policies often mandate vaccine procurement
  and administration, supported by public health
  advisories and educational campaigns that
  effectively increase community engagement and
  compliance. Thus, informed public behavior
  combined with proactive governmental strategies
  enhances the overall demand for monkeypox
  vaccines.
• View Report TOC, Figures and Tables
  https//www.imarcgroup.com/monkeypox-vaccine-marke
  t

7
Report Segmentation

• Breakup by Type
• Replication-competent
• Replication-deficient
• Breakup by Route of Administration
• Subcutaneous
• Percutaneous
• Breakup by Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

8
Report Segmentation

• Breakup by End User
• Hospitals
• Clinics
• Others
• Breakup by Region
• North America
• Asia-Pacific
• Europe
• Latin America
• Middle East and Africa

9
Key Questions Answered in the Report
10
Table of Contents

• 1    Preface2    Scope and Methodology    2.1  
   Objectives of the Study    2.2  
   Stakeholders    2.3    Data Sources       
  2.3.1    Primary Sources        2.3.2  
   Secondary Sources    2.4    Market Estimation 
        2.4.1    Bottom-Up Approach        2.4.2  
   Top-Down Approach    2.5    Forecasting
  Methodology3    Executive Summary4  
   Introduction    4.1    Overview    4.2    Key
  Industry Trends5    Global Monkeypox Vaccine
  Market    5.1    Market Overview    5.2  
   Market Performance    5.3    Impact of
  COVID-19  5.4    Market Forecast
• 6     Market Breakup by Type
• 6.1 Replication-competent
• 6.1.1 Market Trends
• 6.1.2 Market Forecast
• 6.2 Replication-deficient
• 6.2.1 Market Trends
• 6.2.2 Market Forecast
• 7 Market Breakup by Route of Administration
• 7.1 Subcutaneous
• 7.1.1 Market Trends
• 7.1.2 Market Forecast       

11
Table of Contents

• 7.2 Percutaneous
• 7.2.1 Market Trends
• 7.2.2 Market Forecast
• 8 Market Breakup by Distribution Channel
• 8.1 Hospital Pharmacy
• 8.1.1 Market Trends
• 8.1.2 Market Forecast
• 8.2 Retail Pharmacy
• 8.2.1 Market Trends
• 8.2.2 Market Forecast
• 8.3 Online Pharmacy
• 8.3.1 Market Trends
• 8.3.2 Market Forecast
• 8.4 Others
• 8.4.1 Market Trends
• 8.4.2 Market Forecast
• 9 Market Breakup by End User
• 9.1 Hospitals
• 9.1.1 Market Trends

12
Partial List of Clients
13
Partial List of Clients
14
Disclaimer

• 2024 IMARC All Rights Reserved
• This Publication and all its contents unless
  otherwise mentioned are copyrighted in the name
  of International Market Analysis Research and
  Consulting (IMARC). No part of this publication
  may be reproduced, repackaged, redistributed or
  resold in whole or in any part. The publication
  may also not be used in any form or by and means
  graphic electronic or mechanical, including
  photocopying, recording, taping or by information
  storage or retrieval, or by any other form,
  without the express consent of International
  Market Analysis Research and Consulting (IMARC).
• Disclaimer All contents and data of this
  publication, including forecasts, data analysis
  and opinion have been based on information and
  sources believed to be accurate and reliable at
  the time of publishing. International Market
  Analysis Research and Consulting makes no
  representation of warranty of any kind as to the
  accuracy or completeness of any Information
  provided. IMARC accepts no liability whatsoever
  for any loss or damage resulting from opinion,
  errors or inaccuracies if any found this
  publication.
• IMARC, IMARC Group and Global Therapy Insight
  Series are registered trademarks of International
  Market Analysis Research and Consulting. All
  other trademarks used in this publication are
  registered trademarks of their respective
  companies.

15
Contact Us
Visit us at
https//www.imarcgroup.com
1-631-791-1145
sales_at_imarcgroup.com
Stay With Us